about
Renalase - a new marker or just a bystander in cardiovascular disease: clinical and experimental data.Renal support during liver transplantation: when to consider it?Vascular adhesion protein-1 in hemodialysis and hemodiafiltration patients: effect of single hemodialysis session on its level in regard to type of anticoagulantFibroblast growth factor 23, iron and inflammation - are they related in early stages of chronic kidney disease?Renal anemia treatment with ESA in hemodialysis patients in relation to early versus late referral in everyday clinical practice in Central and Eastern European countries: baseline data.Prevention of sudden cardiac death in patients with chronic kidney disease.Urinary tract infections in pregnancy: old and new unresolved diagnostic and therapeutic problems.Prosthetic status and treatment needs for lost masticatory function in haemodialysis patientsBiomarkers of delayed graft function as a form of acute kidney injury in kidney transplantationCardiorenal Syndrome and the Role of the Bone-Mineral Axis and AnemiaHepcidin in anemia and inflammation in chronic kidney disease.Blood pressure levels and stroke: J-curve phenomenon?Renal anaemia treatment in haemodialysis patients in the Central and Eastern European countries in everyday clinical practice follow-up.Hyperglycemia and diabetes have different impacts on outcome of ischemic and hemorrhagic stroke.Use of short prosthesis segments for brachiocephalic arteriovenous fistulas in elderly hemodialysis population.Neutrophil gelatinase-associated lipocalin and hepcidin: what do they have in common and is there a potential interaction?Mechanism of endothelial dysfunction in chronic kidney disease.Current status of the measurement of blood hepcidin levels in chronic kidney disease.Hypertension and kidney disease: is renalase a new player or an innocent bystander?Renalase, hypertension, and kidney - the discussion continues.Renal replacement therapy before, during, and after orthotopic liver transplantation.Peritoneal ultrafiltration in end-stage congestive heart failure.Renalase, kidney and cardiovascular disease: are they related or just coincidentally associated?Copeptin: Pathophysiology and potential clinical impact.Systematic biobanking, novel imaging techniques, and advanced molecular analysis for precise tumor diagnosis and therapy: The Polish MOBIT project.The quest for equilibrium: exploring the thin red line between bleeding and ischaemic risks in the management of acute coronary syndromes in chronic kidney disease patients.Matrix Metalloproteinase Neutrophil Gelatinase-Associated Lipocalin Complex Predicts Atrial Fibrillation Recurrence after Electrical Cardioversion in Obese Patients.Nephrotoxicity of anticancer treatment.Basilic vein transposition in the forearm for secondary arteriovenous fistula.Renal Function Predicts Outcomes in Patients with Ischaemic Stroke and Haemorrhagic Stroke.Intra-individual variability of serum hepcidin-25 in haemodialysis patients using mass spectrometry and ELISA.Patients with atrial fibrillation and coronary artery disease - Double trouble.Do CHA2 DS2 VASc and HAS-BLED scores influence 'real-world' anticoagulation management in atrial fibrillation? 1556 patient registry from the reference cardiology centre.Is there association between changes in eGFR value and the risk of permanent type of atrial fibrillation? Analysis of valvular and non-valvular atrial fibrillation population.Midkine: a novel and early biomarker of contrast-induced acute kidney injury in patients undergoing percutaneous coronary interventions.Cardiac device-related endocarditis in the patient with end-stage renal failure in the course of Fabry disease.Correlation between carotid intima-media thickness and hematocrit and hemoglobin values in renal transplant recipients.A meta-analysis of the role of statins on renal outcomes in patients with chronic kidney disease. Is the duration of therapy important?Fluvastin therapy affects TAFI concentration in kidney transplant recipients.New renal anemia drugs: is there really anything new on the horizon?
P50
Q31107857-D80CF30A-63FB-4670-9C91-59F8050FFF22Q33411257-53CF6802-2B90-4F9E-ACD3-4A503C13E6C3Q33599915-C1E210C7-A7D0-4983-AFFA-4952529A40C9Q33904467-E2059CB2-7F5D-42D9-85B8-AF52ECCE905DQ34005174-E4BF0C3C-3E7D-4A1B-A38A-E5244948BF2FQ34498672-8E01321D-F0D6-4533-B091-A1D594F713D4Q35232225-13703940-377F-45DC-BAA7-541343DB1EF0Q35843963-8EBA0878-9F54-4C2D-B6F5-D4015D793BE5Q35851947-B450492B-8DBC-4CE1-99FA-CD3570463557Q35893998-91E99F2C-7419-4A80-8C26-069C714C4FCAQ36704221-B53EA7D8-7FB3-4018-898E-658843CF5DC1Q37337561-D1B2DBA9-249E-4CB7-8B2E-D31F109C7F93Q37526367-2477AFCA-C95B-49D8-9C59-B00FAEE4F8ECQ37549354-82B5A7D3-640A-421F-89D8-41B64317BAABQ37636828-9DC76D1D-72A7-4518-859A-BC2CDAE7DEB9Q37760704-A57810A6-E6DE-4916-9A3F-8DC3800A7B66Q37769652-11B4A400-1278-49A6-99CD-0F019614E6B2Q37781229-62A464A4-CBD6-45C8-8D5F-ECCC6F492226Q37974066-D837C6AF-B0DD-4083-B899-4B0D87DC2A08Q38042591-0CF67021-30E4-4221-AA86-0203D2723AF5Q38116337-A82B65FF-8941-4512-9330-3B341D60C132Q38187930-A33ABC36-04EA-4233-97AC-09DADB22D289Q38280687-5B1C53B4-DCCD-4E27-BA24-4D4C7FA75992Q38559032-A569619A-DE55-4ED5-810B-D8611794D849Q38710900-D7E988AC-0E3D-4E2B-8D95-9A2B74CEEE13Q38735704-1103A3D1-680C-4CC2-A107-705217B12764Q39085575-33DCE48C-156F-493D-9314-34E4E33CA5AFQ39198933-BBAFA701-7CB7-45E5-BEB9-A9ED96FA04B6Q39433079-8C045EB1-869A-467F-BB9B-A71842CBC95FQ39550871-1311298D-B53E-4DBF-AFB9-2749BD6821C0Q39582910-AA61E93B-12CD-4849-8B4A-7528FADA2BABQ40079099-BA06D403-0B08-4C99-A596-8B6E6E451DFDQ41289704-D9BB200B-CD9C-4D96-A384-6A117F4204C7Q41660205-822E0B99-BA58-4FA1-9227-2C9941DC1A11Q41873436-834436F2-B026-43E5-AF49-E3F20FBD9538Q42912165-8F865AEB-9837-47C6-9AB3-B03122CC9A74Q43778426-ADCF1B9A-C598-4638-B8B0-8A125384FF7AQ43809493-043D38FE-87E8-4657-B9D4-CB30E3254529Q44289710-8A54C7CE-825D-42D7-9071-D9F75C4D1001Q44405723-1F84C8F5-F3D9-41E1-941F-1405837A720F
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Jolanta Malyszko
@ast
Jolanta Malyszko
@en
Jolanta Malyszko
@es
Jolanta Malyszko
@nl
type
label
Jolanta Malyszko
@ast
Jolanta Malyszko
@en
Jolanta Malyszko
@es
Jolanta Malyszko
@nl
prefLabel
Jolanta Malyszko
@ast
Jolanta Malyszko
@en
Jolanta Malyszko
@es
Jolanta Malyszko
@nl
P214
P106
P1153
35074560500
P214
P31
P496
0000-0001-8701-8171
P7859
viaf-311809439